Cyclo Therapeutics Presents Clinical Trial Data on Niemann-Pick Type C Disease

Posted by

Cyclo Therapeutics, Inc. a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, announced the online availability of its poster presentation at the WORLDSymposium (“We’re Organizing Research on Lysosomal Diseases”) to be held in Orlando, Florida, between February 10-13, 2020. The poster presentation (available HERE) is entitled, “Trappsol® Cyclo™ hydroxypropyl beta cyclodextrin administered intravenously in patients with Niemann-Pick Disease Type C reduces cholesterol in liver tissue.” The presentation includes data from the Company’s ongoing Phase I clinical trial in the United States to evaluate Trappsol® Cyclo™ administered intravenously in NPC in subjects 18 years and older (see NCT02939547 for study parameters). The presentation shows that Trappsol® Cyclo™, when provided intravenously at levels as low as 1500 mg/kg, reduces trapped cholesterol in cells of NPC patients.

Cyclo Therapeutics, Inc. Chairman and CEO N. Scott Fine said, “These preliminary data further support the company moving forward as quickly as possible to get the drug to market authorization and begin helping patients.”


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.